Dr. David Tabagari joined the Division of Hospital Medicine as an Instructor in Medicine in July 2024. He was born and raised in Tbilisi, Republic of Georgia, and moved to the United States in 2021 to complete his Internal Medicine residency training. He attended and received his medical degree in 2017 from Tbilisi State Medical University. After graduating, he worked at “Multiprofile Clinic Consilium Medulla” in Tbilisi, Republic of Georgia, as a junior doctor and later as a resident physician in the hematology-oncology program, where he participated in various projects and was working on several major clinical trials. He is currently a co-founder of “Multiprofile Clinic Consilium Medulla” and is using his training and experience to be actively involved in implementing international standards to provide the highest quality medical care for patients in his home country. Dr. Tabagari completed his internship and residency at the University of Missouri School of Medicine in Columbia prior to joining the division in 2024.
Education
- Medical Degree: Tbilisi State Medical University, Tbilisi, Republic of Georgia (2017)
- Residency, Internal Medicine: University of Missouri School of Medicine, Columbia, MO (2023)
Clinical Interests
General internal medicine, inpatient care, hematology and oncology, detection and management of immunotherapeutic adverse events requiring hospitalization
Presentations
Improving USPSF, 2022-2024, Institutional quality improvement project- creating a template to effectively integrate and follow USPSF guidelines in outpatient setting
Predicting Progression-Free Survival of Lung Cancer using RECIST 1.1 vs mRECIST, July 2022, Presentation at Online iRECIST training
Atypical antipsychotics-induced Hypertrigyceridemia, June 2022, Presented to the residency class for continued education
Improving patient’s A1c and BMI by teaching the MyPlate diagram, June 2022, Institutional quality improvement project
Campylobacter-induced Gullian-Barre Syndrome, 2021, Presented to the residency class for continued education
Immunotherapeutic effect of anti-PD-1 inhibitor antibody in patient with SCLC, July 2019, Presentation at Lung Immunotherapy and Foundation Medicine Conference